[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100537757":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":32,"locations":41,"responsibleParty":59,"collaborators":31,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":31,"enrollmentInfo":70,"targetDuration":31,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":44,"whyStopped":31,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Ottawa Heart Institute Research Corporation","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","ACTIVE_COMPARATOR","Participants randomized to receive dexmedetomidine will be started at a dose of 0.3 mcg\u002Fkg\u002Fhr and titrated to a target dose of 1.0 mcg\u002Fkg\u002Fhr. Once the participant reaches their maximum tolerated dose (as decided by the blinded treating physician), they will continue treatment for 48 ± 6 hours. This will be followed by a weaning phase that will similarly be at the discretion of the treating physician.",[13],"Drug: Dexmedetomidine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants randomized to receive placebo will be started on normal saline. In similar fashion to the active comparator, participants will be titrated to their maximal tolerated dose, continue treatment for 48 ± 6 hours, and be weaned at the discretion of the blinded treating physician.",[19],"Drug: Normal saline",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dose range: 0.3 mcg\u002Fkg\u002Fhr to 1 mcg\u002Fkg\u002Fhr.",[9],[26],"Precedex",{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"Normal saline","Programed as dexmedetomidine on infusion pump.",[15],null,[33,38],{"name":34,"role":35,"phone":36,"phoneExt":31,"email":37},"F. Daniel Ramirez, MD MSc","CONTACT","613-696-7402","dramirez@ottawaheart.ca",{"name":39,"role":35,"phone":31,"phoneExt":31,"email":40},"Benjamin Hibbert, MD PhD","hibbert.benjamin@mayo.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"University of Ottawa Heart Institute","RECRUITING","Ottawa","Ontario","K1Y 4W7","Canada","CA",{"type":51,"coordinates":52},"Point",[53,54],-75.69812,45.41117,{"lat":54,"lon":53},[57],{"name":58,"role":35,"phone":36,"phoneExt":31,"email":37},"F Daniel Ramirez, MD",{"type":60,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100537757","phase-3-study-evaluating-dexmedetomidine-in-the-acute-treatment-of-electrical-storm-100537757",false,"NCT06281977","Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm","SEDATE","Inclusion Criteria:\n\n\\- All patients admitted to an intensive care unit with electrical storm over the age of 18 years will be approached for enrollment.\n\nExclusion Criteria:\n\n* Refractory shock lasting for more than 30 minutes unrelated to ventricular arrhythmias (VAs), defined as requiring two or more vasopressors\n* SCAI class D or E cardiogenic shock\n* Cardiac arrest(s) with a no-flow and low-flow total time of greater than 10 minutes prior to recruitment.\n* ST-segment elevation myocardial infarction (STEMI)-induced VA with signs of active ischemia.\n* Bradycardia with heart rate less than 40 beats per minute, bradycardia-induced ventricular tachyarrhythmia, second degree Mobitz type 2 or greater atrioventricular block in the absence of a pacemaker.\n* Pregnancy\n* Known dexmedetomidine allergy or intolerance\n* Inability to obtain consent from patient or substitute decision maker.\n* Patients who have received dexmedetomidine or clonidine during the 24 hours prior to randomization","ALL","18 Years",{"count":71,"type":72},192,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","The objective of this study is to determine if there is a meaningful benefit to using the sedative medication dexmedetomidine in the acute treatment of patients with recurrent ventricular arrhythmias, known as electrical storm. This will be a multi-centre, double-blinded, placebo-controlled, randomized trial. Patients with electrical storm will be randomized to receive 48 to 72 hours of dexmedetomidine or placebo as part of their initial treatment in an intensive care unit.",[78,79,80,81],"Ventricular Tachycardia","Ventricular Arrhythmias","Ventricular Fibrillation","Recurrent Ventricular Tachycardia",[83,9,84,26,85,81,86],"Electrical Storm","Ventricular Electrical Storm","Recurrent Ventricular Arrhythmias","Sedation","2025-12-16",{"date":89,"type":90},"2025-12-17","ACTUAL",{"date":92,"type":90},"2024-05-08",{"date":94,"type":72},"2027-08-01",{"name":5,"class":6},1]